Photo via Unsplash
Every cell in your body carries an electrical address. It is encoded in the voltage across its membrane, in the pattern of ion channels it expresses, in the bioelectric signals it sends to and receives from its neighbors through gap junctions. This address tells the cell where it is in the body, what tissue it belongs to, and how it should behave—whether to divide, to differentiate, to migrate, or to die. In cancer, this address becomes corrupted. The question driving a new field of research is whether it can be rewritten.
Cancer’s Bioelectric Signature
Virtually all cancer cells, across tumor types and tissues of origin, share a common bioelectric feature: they are depolarized. Their resting membrane potential is closer to zero—less negative than the -70 to -90 millivolts typical of their normal counterparts. This depolarization is not a side effect of malignant metabolism; it appears to be a primary driver of cancer cell behavior. Experimentally depolarizing normal cells to cancer-like membrane potentials can cause them to proliferate inappropriately, lose contact inhibition, and invade surrounding tissue—hallmarks of cancer that emerge purely from the change in electrical state, without any genetic mutation.
The converse is equally striking. Hyperpolarizing cancer cells—restoring their membrane potential toward the normal range—can halt their proliferation, reduce their invasiveness, and in some cases trigger apoptosis: programmed cell death. This has been demonstrated in cell culture for breast cancer, melanoma, glioblastoma, and several other cancer types using pharmacological agents that activate potassium channels or inhibit sodium channels in cancer cell membranes. The cancer cells do not revert to normal—their genetic mutations persist—but their behavior normalizes. The electrical state of the cell, rather than its genetic state, appears to determine much of what we recognize as the cancer phenotype.
The Tissue-Level Bioelectric Field
Cancer does not exist in isolation. It develops within tissue that has its own community-level bioelectric organization—voltage gradients, gap junction networks, and extracellular electric field patterns that help maintain normal tissue architecture and suppress abnormal cell behavior. Healthy tissue is electrically organized; cancer disrupts that organization, and the disruption propagates.
Research using voltage-sensitive dyes and fluorescent protein reporters has revealed that pre-malignant cells—cells that have acquired some cancer-associated mutations but have not yet formed invasive tumors—often exist within normal-looking tissue as bioelectrically distinct islands. Their membrane potential differs from surrounding cells, and this difference is detectable before any morphological abnormality is visible. This finding suggests that bioelectric imaging might enable cancer detection at earlier stages than any current modality, catching malignant transformation at the bioelectric signature stage rather than waiting for the structural changes that make tumors visible to conventional imaging.
The extracellular electric fields generated by tissues also influence cancer behavior. Tumor cells are electrotactic—they migrate directionally in applied electric fields, typically toward the cathode. This electrotaxis is thought to contribute to the directional spread of tumors through tissue, as the fields generated by wounds and inflammation guide metastatic cells toward specific destinations. Disrupting electrotaxis pharmacologically—using agents that alter the cancer cell’s directional response to electric fields—has reduced metastasis in animal models, pointing to the bioelectric control of cell migration as a potential therapeutic target.
Rewriting the Address: Therapeutic Possibilities
The most direct therapeutic implication of cancer’s bioelectric vulnerability is pharmacological hyperpolarization of tumor tissue. Several approved drugs—primarily those developed for cardiac arrhythmia or other indications—happen to activate ion channels in ways that hyperpolarize cells. Some of these drugs have shown anticancer activity in preclinical studies at doses relevant to their existing clinical use, suggesting that their bioelectric effects on tumor cells may contribute to antitumor activity that was not recognized when the drugs were developed.
More targeted approaches are in development. Ion channel subtypes that are differentially expressed in tumor cells compared to surrounding normal tissue—particularly certain sodium channel variants found in aggressive breast cancer and prostate cancer—represent potential targets for drugs that would depolarize or otherwise electrically disable cancer cells with selectivity. The pharmaceutical challenge is achieving sufficient selectivity in ion channel targeting to avoid disrupting the electrical function of normal excitable tissue—particularly cardiac muscle and neurons—while achieving therapeutic concentrations in solid tumors.
Physical devices offer another route. Tumor-treating fields—alternating electric fields delivered to the scalp through electrode arrays—are an FDA-approved treatment for glioblastoma, the most aggressive brain tumor, where they improve survival when combined with standard chemotherapy. The mechanism involves disruption of cell division through physical forces on the charged components of the mitotic spindle. This is a direct bioelectrical intervention in cancer biology, and its clinical success is proof-of-principle that manipulating the electrical environment of tumors can produce meaningful clinical benefit.
Rewriting the body’s electrical address system to stop cancer is not a single therapy but a framework for thinking about cancer biology that is only now being systematically explored. The tools to read and write bioelectric states in tissues—voltage-sensitive imaging, targeted ion channel pharmacology, external field devices—are advancing rapidly. The evidence that cancer’s behavior is determined in part by its electrical state, and that that state is reversible, is strong enough to justify aggressive investigation. The goal is not to replace genetic and immunological approaches to cancer treatment but to add a new dimension: treating the electrical corruption that enables tumor cells to misbehave within tissue that would otherwise constrain them.
Rewriting the body’s electrical address system to stop cancer is not a single therapy but a research framework that is only now being systematically explored. The tools to read and write bioelectric states in tissues—voltage-sensitive fluorescent imaging, targeted ion channel pharmacology, external field devices—are advancing rapidly. The evidence that cancer’s behavior is partly determined by its electrical state, and that this state can be altered, is strong enough to justify aggressive investigation. The goal is not to replace genetic and immunological approaches but to add a dimension: treating the electrical disorganization that allows tumor cells to misbehave within tissue that would otherwise constrain them. Getting that constraint right—restoring the electrical social order of normal tissue—may prove as important as targeting the genetic lesions that initiated the malignant process.
That is the promise bioelectric oncology is beginning to deliver on—treating the electrical disorganization of cancer rather than just its genetic consequences.
Sources and Further Reading
- Yang, M. & Bhanu Bhanu, J. (2013). Bioelectrical control of cancer. Cell Cycle.
- Blackiston, D.J. et al. (2011). Serotonergic stimulation induces nerve growth and promotes visual learning via posterior eye grafts in a vertebrate model of induced sensory plasticity. Neuropsychopharmacology.
- Chernet, B.T. & Levin, M. (2013). Endogenous voltage potentials and the microenvironment of the embryo and tissue. Current Topics in Developmental Biology.